The Latest in News

Len plus anti-CD19 Mab MOR208 active against advanced DLBCL

June 20, 2017

Aggressive Lymphomas

Two SNPs linked to survival in R-CHOP–treated DLBCL

June 15, 2017

Aggressive Lymphomas

Severe health conditions decline in childhood cancer survivors

June 3, 2017

Aggressive Lymphomas

Subcutaneous rituximab safe, effective for follicular lymphoma

May 9, 2017

Indolent Lymphoma

Cord blood/placental cell combo induces rapid immune recovery

May 3, 2017

Aggressive Lymphomas

Ibrutinib monotherapy data in previously treated MZL is available

May 2, 2017

Indolent Lymphoma

Maintenance lenalidomide prolongs progression-free survival in DLBCL

April 30, 2017

Aggressive Lymphomas

In mantle cell lymphoma, triple therapy proves too toxic

April 24, 2017

Aggressive Lymphomas

Prognostic tool may allow tailored therapy for Hodgkin lymphoma

April 21, 2017

Aggressive Lymphomas

Thousands expected to get CAR T-cells by 2018

April 20, 2017

Aggressive Lymphomas

Waldenström macroglobulinemia panel advises on IgM paraproteinemic neuropathies

April 19, 2017

Indolent Lymphoma

Obinutuzumab vs. rituximab weighed as follicular lymphoma therapy

April 18, 2017

Indolent Lymphoma

FDA grants Hodgkin lymphoma indication for pembrolizumab

March 15, 2017

Aggressive Lymphomas

Connective tissue diseases reported in patients receiving immune checkpoint inhibitors

March 3, 2017

Aggressive Lymphomas

Adding rituximab to reduced intensity conditioning boosts PFS

March 2, 2017

Aggressive Lymphomas